Cargando…

In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations

PURPOSE: Patients with primary immunodeficiency (PID) often receive immunoglobulin replacement therapy (IgRT). Physicians and patients have the choice between various methods of administration. For subcutaneous immunoglobulin infusions, patients may use an automated pump (P) or push the plunger of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cozon, Grégoire Jacques Noël, Clerson, Pierre, Dokhan, Annaïk, Fardini, Yann, Sala, Taylor Pindi, Crave, Jean-Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875589/
https://www.ncbi.nlm.nih.gov/pubmed/29618922
http://dx.doi.org/10.2147/PPA.S156983
_version_ 1783310376361787392
author Cozon, Grégoire Jacques Noël
Clerson, Pierre
Dokhan, Annaïk
Fardini, Yann
Sala, Taylor Pindi
Crave, Jean-Charles
author_facet Cozon, Grégoire Jacques Noël
Clerson, Pierre
Dokhan, Annaïk
Fardini, Yann
Sala, Taylor Pindi
Crave, Jean-Charles
author_sort Cozon, Grégoire Jacques Noël
collection PubMed
description PURPOSE: Patients with primary immunodeficiency (PID) often receive immunoglobulin replacement therapy (IgRT). Physicians and patients have the choice between various methods of administration. For subcutaneous immunoglobulin infusions, patients may use an automated pump (P) or push the plunger of a syringe (rapid push [RP]). P infusions are performed once a week and last around 1 hour. RP decreases the duration of administration, but requires more frequent infusions. PATIENTS AND METHODS: Eight out of 30 patients (coming from a single center) who had participated in the cross-over, randomized, open-label trial comparing P and RP participated in a focus group or underwent in-depth interviews. Patients had a long history of home-based subcutaneous immunoglobulin using P. The trial suggested that RP had slightly greater interference on daily life than P, but similar efficacy and better cost-effectiveness. When asked about the delivery method they had preferred, around one-third of patients pointed out RP rather than P. In-depth interviews may reveal unforeseen reasons for patients’ preferences. RESULTS: Interviews underlined the complexity of the relationship that the patients maintain with their disease and IgRT. Even if they recognized the genetic nature of the disease and claimed PID was a part of them, patients tried not to be overwhelmed by the disease. IgRT by P was well integrated in patients’ routine. By contrast, RP too frequently reminded the patients of their disease. In addition, some patients pointed out the difficulty of pushing the plunger due to the viscosity of the product. Coming back too frequently, RP was not perceived as time saving over a week. Long-lasting use of P could partly explain patients’ reasonable reluctance to change to RP. CONCLUSION: In-depth interviews of PID patients highlighted unforeseen reasons for patients’ preference that the physician needs to explore during the shared medical decision-making process.
format Online
Article
Text
id pubmed-5875589
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-58755892018-04-04 In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations Cozon, Grégoire Jacques Noël Clerson, Pierre Dokhan, Annaïk Fardini, Yann Sala, Taylor Pindi Crave, Jean-Charles Patient Prefer Adherence Original Research PURPOSE: Patients with primary immunodeficiency (PID) often receive immunoglobulin replacement therapy (IgRT). Physicians and patients have the choice between various methods of administration. For subcutaneous immunoglobulin infusions, patients may use an automated pump (P) or push the plunger of a syringe (rapid push [RP]). P infusions are performed once a week and last around 1 hour. RP decreases the duration of administration, but requires more frequent infusions. PATIENTS AND METHODS: Eight out of 30 patients (coming from a single center) who had participated in the cross-over, randomized, open-label trial comparing P and RP participated in a focus group or underwent in-depth interviews. Patients had a long history of home-based subcutaneous immunoglobulin using P. The trial suggested that RP had slightly greater interference on daily life than P, but similar efficacy and better cost-effectiveness. When asked about the delivery method they had preferred, around one-third of patients pointed out RP rather than P. In-depth interviews may reveal unforeseen reasons for patients’ preferences. RESULTS: Interviews underlined the complexity of the relationship that the patients maintain with their disease and IgRT. Even if they recognized the genetic nature of the disease and claimed PID was a part of them, patients tried not to be overwhelmed by the disease. IgRT by P was well integrated in patients’ routine. By contrast, RP too frequently reminded the patients of their disease. In addition, some patients pointed out the difficulty of pushing the plunger due to the viscosity of the product. Coming back too frequently, RP was not perceived as time saving over a week. Long-lasting use of P could partly explain patients’ reasonable reluctance to change to RP. CONCLUSION: In-depth interviews of PID patients highlighted unforeseen reasons for patients’ preference that the physician needs to explore during the shared medical decision-making process. Dove Medical Press 2018-03-26 /pmc/articles/PMC5875589/ /pubmed/29618922 http://dx.doi.org/10.2147/PPA.S156983 Text en © 2018 Cozon et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Cozon, Grégoire Jacques Noël
Clerson, Pierre
Dokhan, Annaïk
Fardini, Yann
Sala, Taylor Pindi
Crave, Jean-Charles
In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
title In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
title_full In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
title_fullStr In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
title_full_unstemmed In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
title_short In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
title_sort in-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875589/
https://www.ncbi.nlm.nih.gov/pubmed/29618922
http://dx.doi.org/10.2147/PPA.S156983
work_keys_str_mv AT cozongregoirejacquesnoel indepthinterviewsofpatientswithprimaryimmunodeficiencywhohaveexperiencedpumpandrapidpushsubcutaneousinfusionsofimmunoglobulinsrevealnewinsightsontheirpreferenceandexpectations
AT clersonpierre indepthinterviewsofpatientswithprimaryimmunodeficiencywhohaveexperiencedpumpandrapidpushsubcutaneousinfusionsofimmunoglobulinsrevealnewinsightsontheirpreferenceandexpectations
AT dokhanannaik indepthinterviewsofpatientswithprimaryimmunodeficiencywhohaveexperiencedpumpandrapidpushsubcutaneousinfusionsofimmunoglobulinsrevealnewinsightsontheirpreferenceandexpectations
AT fardiniyann indepthinterviewsofpatientswithprimaryimmunodeficiencywhohaveexperiencedpumpandrapidpushsubcutaneousinfusionsofimmunoglobulinsrevealnewinsightsontheirpreferenceandexpectations
AT salataylorpindi indepthinterviewsofpatientswithprimaryimmunodeficiencywhohaveexperiencedpumpandrapidpushsubcutaneousinfusionsofimmunoglobulinsrevealnewinsightsontheirpreferenceandexpectations
AT cravejeancharles indepthinterviewsofpatientswithprimaryimmunodeficiencywhohaveexperiencedpumpandrapidpushsubcutaneousinfusionsofimmunoglobulinsrevealnewinsightsontheirpreferenceandexpectations